Animalcare Group (ANCR) Fair Value & Analysis
Healthcare · GB · Market cap 229M GBX
Fair value as of: Jun 24, 2026
Analysis
Animalcare Group (ANCR) currently trades at p3.32, while our model-based Fair Value estimate is p1.62 — implying the stock looks roughly 51.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals for the companion animal, production animal, and equine veterinary markets in Europe, the Asia-Pacific, and internationally. It operates through Animalcare Europe and Randlab segments. The company offers Orozyme, an enzymatic toothpaste for dental care in cats and dogs; Danilon, an oral treatment for pain in horses; Dinalgen, an injectable treatment for pain in cattle, pigs, and horses; Aqupharm, a dehydration treatment for cats, dogs, cattle, goats, horses, pigs, rabbits, and sheep; Ulcershield, a treatment and prevention of gastric ulcers in horses; Daxocox, a treatment of osteoarthritis pain and inflammation in dogs; Plaqtiv+, a biofilm-based dental care for cats and dogs; Thiamacare, a treatment for hyperthyroidism in cats; Hemo, an injectable nutritional solution for horses; and Cosequin, a complementary feed for dogs and cats to strengthen and protect joints. It also provides nutritional …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Animalcare Group (ANCR) undervalued?
What is the fair value of ANCR?
What is the quality score of ANCR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.